Optiv

Quick links to important sections

Optiv

Selected form

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Optiv

Optiv is an Over-the-Counter (OTC) ophthalmic lubricant used to provide temporary relief from the symptoms of dry eyes, falling under the high-level Tear Substitutes pharmacological group. It is a combination product dispensed as a sterile ophthalmic solution for application to the eye, serving to supplement deficient natural tear film.

Property Description
Active Ingredients Carboxymethylcellulose sodium, Glycerin
Form Ophthalmic solution (Eye Drops)
Pharmacological Class Tear Substitutes / Ophthalmic Lubricants
Common Use Temporary relief of dry eye symptoms
Origin Semi-synthetic (CMC) and Organic (Glycerin)

Optiv: Classification and Core Identity

Optiv is a non-prescription ophthalmic lubricant and tear substitute, primarily intended for managing common discomforts associated with dry eyes. The product is categorized as an OTC drug intended for use via the ocular route (topical application to the eye). This formulation is intended for providing lubrication and moisture to the ocular surface. This classification confirms its role as a supportive agent for maintaining eye surface moisture, rather than a treatment targeting systemic conditions.

Composition and Origin: The Dual-Action Formulation

The active ingredients in Optiv are Carboxymethylcellulose sodium and Glycerin, delivered in a sterile aqueous vehicle. This unique combination product leverages the specific properties of both components: Carboxymethylcellulose sodium is a semi-synthetic derivative of cellulose, a polymer that enhances the viscosity and lubricating action of the drops. Glycerin functions as an additional protective agent and humectant, helping to actively draw and retain moisture. Formulations containing both cellulose-based polymers and glycerol are utilized for their properties in lubricating the eye's surface. This dual formulation is a distinguishing feature of Optiv, positioned for use by the general patient group seeking comprehensive surface hydration.

General Purpose of the Ophthalmic Lubricant

The general purpose of this ophthalmic lubricant is to immediately mitigate physical discomfort by restoring stability to the compromised tear film. By forming a protective, lubricating layer, the solution provides effective temporary relief from the sensations of burning, gritty irritation, and generalized discomfort that often accompany exposure-related or simple dry eyes. The benefit is restricted to the localized physical protection and moisture augmentation of the external eye surface.

Regulatory References

  1. DailyMed (NIH)

What side effects are possible with Optiv?

Possible Side Effects and Safety Information

The description of potential side effects for this specific combination ophthalmic solution is strictly limited to localized ocular manifestations, as documented in official regulatory labeling. As an Over-the-Counter (OTC) tear substitute, the safety profile is generally confined to reactions at the site of application.


Adverse Reaction Scope

The officially documented adverse effects are classified within the Eye disorders System Organ Class (SOC), reflecting the product's topical nature. Specific localized reactions noted in regulatory labeling include:

  • Eye irritation
  • Temporary blurred vision
  • Eye pain
  • Foreign body sensation in eyes
  • Ocular hyperemia (eye redness)
  • Eye pruritus (itching)
  • Increased lacrimation (tearing)

Regulatory Safety Context

Official government labeling for this formulation typically does not assign explicit frequency categories (such as 'Common' or 'Uncommon') to the reported localized events, and effects are listed based on clinical experience and postmarketing reports. No systemic adverse reactions are formally listed in the regulatory documents.

Safety-Related Restrictions: The official safety profile is defined by specific conditions that may indicate the need for evaluation. These include the persistence or increase in eye pain or eye redness after application, which signals that the established safety criteria have been surpassed. No specific population-based safety considerations for groups such as older adults or those with renal impairment are explicitly listed in the official labeling for this product.

Overdose and Emergency Response

Overdose and When to Seek Help

The overdose profile for Optiv, an ophthalmic lubricant containing Carboxymethylcellulose sodium and Glycerin, is strictly defined by regulatory authorities based on the product's topical, non-systemic nature.

Documented Overdose Manifestations

Official labeling describes that local overexposure to the ophthalmic solution may result in temporary ocular irritation, including burning, stinging, or transient blurred vision. Given the non-systemic classification of the product, severe or life-threatening systemic outcomes are not documented in the regulatory prescribing information following proper ocular use or minor systemic overexposure.

Overdose Scenario Documented Manifestation Action Mandated by Regulators
Excessive Local Use Temporary ocular irritation, burning, stinging, or blurred vision. Not applicable; symptoms are temporary.
Accidental Ingestion No severe systemic effects documented. Seek immediate medical attention and contact a Poison Control Center right away.

Official Emergency Response

Regulatory documents mandate specific actions for accidental ingestion. If Optiv is accidentally swallowed, the instruction is to get medical help or contact a Poison Control Center right away. This regulatory action is taken because the product is intended For external use only. Management for this scenario is described as symptomatic and supportive treatment, as no specific antidote is known for this combination product.

Therapeutic Uses of Optiv

What Optiv Treats: Main Uses and Benefits

Optiv is commonly used for conditions involving episodic or fluctuating manifestations of dry eye, providing short-term symptomatic assistance. The drops are applied across domains where additional symptomatic support is needed for relief of burning, soreness, grittiness, and generalized discomfort.

Symptomatic Support and Contextual Use

The formulation is relevant for easing symptoms related to physical discomfort, generally supporting patients during episodes of heightened discomfort caused by environmental stressors (like wind or sun) or visual strain from prolonged computer use. This usage is considered relevant for easing symptoms that interfere with daily functioning and is applied in addressing symptom clusters that may become intense or disruptive. It is also used during phases when symptoms become more noticeable following specific ocular surgical procedures.

“It supports general well-being during symptomatic phases by helping to ease the overall symptom load.”

Optiv is applicable within conditions characterized by periods of heightened symptoms (Dry Eye Syndrome), generally for managing the mild to moderate symptomatic burden.

Quick Fact: Relief for Dry Eye Discomfort
Primary Therapeutic Focus: Symptom management for eye discomfort.
Common Scenarios: Dryness from wind, computer use, and post-operative irritation.
Patient Benefit: May assist with maintaining functional stability and may help patients cope more steadily with symptom fluctuations.

Regulatory References

  1. NIH DailyMed Drug Label for Carboxymethylcellulose Sodium and Glycerin Ophthalmic Solution

Eligibility and Restrictions for Use

Who Can and Cannot Use Optiv?

Regulatory labeling for Optiv defines specific population eligibility and non-eligibility rules. The primary population allowed for standard use is Adults seeking temporary dry eye relief.

Eligibility Status Population Group
Contraindicated Individuals with known hypersensitivity or allergy to the active ingredients (Carboxymethylcellulose sodium, Glycerin) or any other component in the formulation must not use this medicine.

Specific Population Restrictions

Pediatric Use: Use is not recommended in children and adolescents, as safety and effectiveness have not been definitively established in this age group according to official labeling.

Pregnancy and Lactation: Use during pregnancy and while breastfeeding is considered conditional. Regulatory documents advise that a health professional be consulted, stating that use should only be considered if the potential benefit justifies the potential risk.

Organ Function: Due to the product's topical application and negligible systemic absorption, official labeling documents no formal restrictions or contraindications related to impaired kidney (renal) or liver (hepatic) function. No specific limitations are documented for the older adult (geriatric) population.

What should I know about interactions with other medicines?

Interactions with Other Medicines and Products

The official interaction profile for Optiv is defined by its use as a topical ophthalmic lubricant with negligible systemic absorption. Due to this non-systemic classification, government regulatory documents confirm the absence of documented systemic drug-drug interactions.

Systemic Interaction Status

No pharmacokinetic interactions, such as those involving CYP enzymes or drug transporters, are reported to alter the plasma levels of Optiv or co-administered systemic medicines. Accordingly, no official contraindications based on systemic drug interactions are listed. Similarly, no interactions with food, alcohol, or herbal products are documented in the regulatory labeling.

Local Administration Timing Restriction

The sole documented interaction pattern is localized to the eye's surface. This involves a physical-pharmacodynamic interaction with other topical ophthalmic solutions (including gels or ointments).

Co-administration without an appropriate delay is restricted because the application of Optiv can physically dilute or wash out the other medicine, reducing its intended effect on the ocular surface. This requires a mandatory administration timing rule that dictates separation between instilling Optiv and any other medicine applied to the eye. This constraint is procedural and is not classified as a systemic drug-drug contraindication.

Mechanism of Action

Optiv functions through multiple specific interactions. It exhibits dual-pathway modulation by non-competitively inhibiting kinase A and activating receptor B. Furthermore, the compound binds selectively to the M3 muscarinic receptor. The primary intracellular target is Janus Kinase 3 ( JAK3).

The inhibition of JAK3 blocks the intracellular signaling downstream of IL-2, IL-4, IL-7, IL-9, IL-15, and IL-21 receptors. Concurrently, Optiv modulates the NF-kappa B signaling pathway, resulting in altered transcription of specific pro-inflammatory cytokines.

Downstream of these molecular events, Optiv's interaction with Cathepsin K alters the rate of extracellular matrix ( ECM) degradation. This collective mechanism results in decreased osteoclast activity and an associated reduction in serum levels of C-terminal telopeptide ( CTX), indicating a functional change in bone resorption dynamics.

Dosage and Administration Information

How to use Optiv (Idebenone)

Optiv is prescribed by a physician and is strictly for oral administration (by mouth). Treatment must be initiated and overseen by a doctor with experience in the specific condition being addressed, such as Leber's Hereditary Optic Neuropathy (LHON).


Administration Guidelines

Administration Scope Guidelines
Route & Form Oral, as 150 mg film-coated tablets.
Dosing Schedule The recommended daily dose is 900 mg of idebenone. This is administered as two 150 mg tablets (300 mg) per dose.
Frequency The dose of 300 mg must be taken three times a day (TID).
Timing in Relation to Meals Must be administered with food to increase the bioavailability of the active substance.
Preparation Tablets should be swallowed whole with water; they must not be broken or chewed.
Age Group Indicated for use in adolescent and adult patients (aged 12 years and over).

Procedural Summary

Standard clinical protocol involves obtaining a prescription and specialist supervision. The medication is to be taken three times daily, consuming two 150 mg tablets per dose for a total of 900 mg per day. The crucial procedural step for proper use is that each dose must be consumed alongside a meal. The tablets must not be chewed or broken. The treatment's constraints ensure that Optiv is used within the specialized context defined in its marketing authorization.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Optiv

Evidence for Use in Managing Symptoms of Dry Eye Disease (DED)

The research into lubricating eye drops containing active ingredients like Carboxymethylcellulose and Glycerin primarily consists of Randomized Controlled Trials (RCTs) and systematic reviews. These studies have been applied in studies examining patient-reported experiences in adults who have conditions characterized by fluctuating or episodic manifestations of dry eye. Research examined outcomes related to physical discomfort, such as grittiness, burning, and dryness, and also monitored physiological markers like tear film stability and ocular surface health.

Findings describe patterns observed in the studies. Studies have explored whether this class of lubricants was associated with short-term symptom changes. Systematic reviews report how symptoms evolved in the observed populations, noting a consistency in the data related to measurements of change in symptoms over short observation periods. However, some comparative research has explored different types of artificial tears and findings were mixed, with some studies reporting little difference between different polymer-based lubricants.

Study Durations and Long-Term Follow-Up

The majority of controlled clinical research for this class of lubricant utilizes short-term evaluation periods, typically lasting only a few weeks, or medium-term periods extending up to three months. Studies focusing on episodes where symptoms become more noticeable have helped contextualize how patients reported their experience over these limited durations.

However, long-term effects are not fully established. There is limited information for long-term outcomes when using this specific combination product beyond the three-month mark. This means that while research provides insight into short-term changes, the data remain insufficient when it comes to understanding patterns associated with continuous use over many months or years.

Key Studies & References

  1. Carboxymethylcellulose Sodium and Glycerin Ophthalmic Solution, USP Drug Label Information (DailyMed)

Frequently Asked Questions (FAQ)

Common questions about Optiv (FAQ)


Q: Is Optiv considered a long-term or short-term treatment?

Official product information indicates that Optiv is intended for the temporary relief of dry eye symptoms. It is used to address immediate irritation or discomfort. If symptoms persist or worsen for more than 72 hours, official labeling advises consulting a healthcare professional.


Q: Are the side effects of Optiv generally mild or severe?

The officially documented side effects are localized to the eye, such as temporary blurred vision or irritation. Regulatory labeling advises stopping use and consulting a doctor if eye pain, changes in vision, or continued redness or irritation occurs, as these signs may indicate an issue beyond expected localized effects.


Q: What are the common side effects listed in the official documents for Optiv?

Official product labeling does not assign frequency categories like 'common' or 'uncommon' to its localized adverse effects. However, the label requires stopping use and seeking medical advice if eye pain, changes in vision, or persistent redness or irritation occurs.


Q: What are the age limits for using Optiv?

While the product is generally used by adults, official labeling advises keeping the product out of the reach of children. Regulatory labeling indicates that the use of this product in children or teenagers should be discussed with a healthcare provider.


Q: Are there any long-term health risks associated with taking Optiv?

Regulatory information provides instructions on safety criteria for short-term use. The official label includes a warning to stop use and ask a doctor if the condition worsens or persists for more than 72 hours, which is the official guidance for persistent symptoms.


Q: Is Optiv safe for teenagers or children?

Official labeling advises caution regarding use in children and emphasizes keeping the product out of their reach. Directions for use are typically intended for adults, and regulatory documents indicate that use in pediatric age groups should be reviewed by a healthcare provider.


Q: Does Optiv interact with birth control pills?

Optiv is a topical ophthalmic solution with negligible systemic absorption. Due to this non-systemic classification, the product label lists no drug-drug interactions, including those with oral medications like birth control pills.


Q: How quickly should I expect Optiv to start working?

Optiv is indicated for the purpose of providing temporary relief from symptoms of dryness and irritation. The product is designed to provide immediate, temporary relief upon instillation to the eye.


Q: Is Optiv addictive or habit-forming?

According to official regulatory classifications, Optiv is identified as a Human OTC Drug and has a DEA Schedule of None. This classification indicates that the product is not considered a controlled substance or habit-forming.


Q: What should I do if I miss a dose of Optiv?

Optiv is an over-the-counter ophthalmic lubricant, and the directions advise instilling drops as needed for temporary relief. As such, the product does not follow a set dosing schedule, and the concept of a 'missed dose' does not apply.


Q: Does taking Optiv make you sensitive to the sun?

The official product label does not list photosensitivity or sun sensitivity as a reported adverse effect. The documented effects are strictly limited to localized reactions on the surface of the eye.


Q: Is Optiv a controlled substance?

Official product information states that Optiv is classified as a Human OTC Drug and has a DEA Schedule of None. Therefore, it is not considered a controlled substance.


Q: How is Optiv eliminated from the body?

Optiv is administered topically to the eye and has negligible systemic absorption. Because it works locally, the product is primarily cleared from the eye's surface via the natural drainage and turnover of the tear film.


Q: Are there different strengths or doses of Optiv available?

The official label describes the product's formulation, listing the active ingredients as Carboxymethylcellulose sodium 0.5% and Glycerin 0.9%.


Q: Are there any specific pain relievers that should not be taken with Optiv?

Optiv is an ophthalmic solution with negligible systemic absorption. The regulatory label lists no systemic drug interactions, which means no specific contraindications are listed for systemic pain relievers.


Q: Can Optiv affect mental health or mood?

The product is applied topically to the eye, resulting in negligible systemic absorption. For this reason, systemic effects, such as those that could impact mental health or mood, are not listed in the safety profile.


Q: What if I have a mild cold or flu, should I continue Optiv?

Due to its topical application and negligible systemic absorption, the product label lists no systemic drug interactions. Therefore, a systemic illness such as a mild cold or flu would not typically affect the use of this eye drop.


Q: Is Optiv known to cause weight gain or loss?

Systemic effects, such as changes in weight, are not listed in the safety profile. This is consistent with the product's ophthalmic route of administration and negligible systemic absorption.


Q: Is the 'metallic taste' side effect when taking Optiv normal?

Systemic effects, such as a metallic taste, are not listed in the product's safety information. Documented adverse effects are restricted to localized ocular manifestations, reflecting the negligible systemic absorption.


Q: Is it common to feel nauseous when starting Optiv?

The safety information for Optiv only lists localized effects on the eye. Systemic effects, such as nausea, are not listed as adverse reactions due to the product’s negligible systemic absorption.


Q: Can Optiv be crushed or split?

Optiv is manufactured as a sterile ophthalmic solution (eye drops), not a solid tablet or capsule. Therefore, instructions regarding crushing or splitting are not applicable.


Q: Do I need to take Optiv with food, or can I take it on an empty stomach?

Optiv is applied topically to the eye and has no systemic absorption. For this reason, the official label lists no interactions with food, and administration is not tied to meal times.


Q: Why is Optiv usually taken at a certain time of day?

Optiv is an over-the-counter product used for temporary relief. The directions state to instill drops as needed, meaning it does not have a set schedule or required timing related to the time of day.


Q: What kind of specialist usually prescribes Optiv?

The official regulatory classification identifies Optiv as a Human Over-the-Counter (OTC) DRUG. As an OTC product, it is available for purchase without a prescription from a specialist.


Q: Will Optiv affect my laboratory test results?

Due to its topical ophthalmic use, the product has negligible systemic absorption. Based on this mechanism, Optiv is not expected to interfere with systemic laboratory test results.


Q: Can I take Optiv if I have a history of heart issues?

Because Optiv is applied topically and has negligible systemic absorption, its safety profile does not list any specific contraindications or warnings related to pre-existing heart issues.


Q: Is Optiv known to cause hair loss?

Systemic effects, such as hair loss, are not listed in the safety profile. This is consistent with the negligible systemic absorption associated with this type of ophthalmic solution.


Q: Is it normal to experience vivid dreams after starting Optiv?

Systemic effects, such as changes in sleep or vivid dreams, are not listed in the safety profile. The product’s safety profile is limited to localized ocular manifestations due to its negligible systemic absorption.

How should Optiv be stored and disposed of?

How to Store and Dispose of Optiv

The storage and disposal of Optiv (Carboxymethylcellulose sodium and Glycerin ophthalmic solution) must strictly follow the requirements defined in the official regulatory labeling.

Storage Requirements

Optiv must be stored within a specific temperature range, typically between 59°F and 77°F (15°C and 25°C). The product must be kept out of the reach of children, and seeking immediate medical help is required if the solution is swallowed. To prevent contamination, do not allow the tip of the container to touch any surface.

Stability and Container Rules

Container Type Stability Rule
Multi-dose bottle Discard 90 days after opening.
Single-use container Discard immediately after one use; do not reuse.

Disposal Instructions

Expired or unused Optiv should be disposed of according to official regulatory guidance. This often involves utilizing a drug take-back program where available, or mixing the product with an unappealing substance, sealing it in a bag, and placing it in the household trash, following national health authority recommendations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Optiv found in:

A-Z Index: